Goldman Sachs Group Inc United Therapeutics Corp Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in United Therapeutics Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 77,338 shares of UTHR stock, worth $28.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77,338
Previous 80,710 4.18%
Holding current value
$28.6 Million
Previous $25.7 Million 7.79%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$311.04 - $363.55 $1.05 Million - $1.23 Million
-3,372 Reduced 4.18%
77,338 $27.7 Million
Q2 2024

Aug 13, 2024
BUY
$228.26 - $319.04 $5.08 Million - $7.09 Million
22,234 Added 38.02%
80,710 $25.7 Million
Q1 2024

May 15, 2024
SELL
$210.76 - $249.51 $10 Million - $11.9 Million
-47,653 Reduced 44.9%
58,476 $13.4 Million
Q4 2023

Feb 13, 2024
SELL
$214.88 - $256.94 $1.95 Million - $2.33 Million
-9,060 Reduced 7.87%
106,129 $23.3 Million
Q3 2023

May 14, 2024
BUY
$211.82 - $248.24 $1.92 Million - $2.25 Million
9,060 Added 8.54%
115,189 $26 Million
Q3 2023

Nov 14, 2023
SELL
$211.82 - $248.24 $15.2 Million - $17.8 Million
-71,814 Reduced 38.4%
115,189 $26 Million
Q2 2023

May 14, 2024
BUY
$205.19 - $232.99 $10.6 Million - $12 Million
51,557 Added 38.06%
187,003 $41.3 Million
Q2 2023

Aug 14, 2023
BUY
$205.19 - $232.99 $10.6 Million - $12 Million
51,557 Added 38.06%
187,003 $41.3 Million
Q1 2023

May 14, 2024
SELL
$212.99 - $276.17 $37.6 Million - $48.8 Million
-176,693 Reduced 56.61%
135,446 $30.3 Million
Q1 2023

May 11, 2023
SELL
$212.99 - $276.17 $37.6 Million - $48.8 Million
-176,693 Reduced 56.61%
135,446 $30.3 Million
Q4 2022

May 14, 2024
BUY
$205.95 - $280.43 $24.3 Million - $33.1 Million
117,912 Added 60.71%
312,139 $86.8 Million
Q4 2022

Feb 13, 2023
BUY
$205.95 - $280.43 $24.3 Million - $33.1 Million
117,912 Added 60.71%
312,139 $86.8 Million
Q3 2022

May 14, 2024
SELL
$203.3 - $244.17 $2.7 Million - $3.24 Million
-13,265 Reduced 6.39%
194,227 $40.7 Million
Q3 2022

Nov 10, 2022
SELL
$203.3 - $244.17 $2.7 Million - $3.24 Million
-13,265 Reduced 6.39%
194,227 $40.7 Million
Q2 2022

May 14, 2024
BUY
$174.81 - $241.14 $17.7 Million - $24.4 Million
101,363 Added 95.51%
207,492 $48.9 Million
Q2 2022

Aug 15, 2022
BUY
$174.81 - $241.14 $5.97 Million - $8.24 Million
34,164 Added 19.71%
207,492 $48.9 Million
Q1 2022

May 16, 2022
BUY
$166.16 - $213.96 $707,010 - $910,399
4,255 Added 2.52%
173,328 $31.1 Million
Q4 2021

Feb 14, 2022
SELL
$184.32 - $216.08 $21 Million - $24.6 Million
-113,763 Reduced 40.22%
169,073 $36.5 Million
Q3 2021

Nov 10, 2021
BUY
$179.86 - $214.88 $50.9 Million - $60.8 Million
282,836 New
282,836 $52.2 Million

Others Institutions Holding UTHR

# of Institutions
671
Shares Held
42.4M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.8B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email